Pro Medicus Ltd

Pro Medicus operates with a fully diluted share count of 104,469,963 shares, matching its basic share count, indicating no dilution from stock options or convertible securities. The company's market capitalization of AUD 13.74 billion reflects a market price of AUD 131.48 per share, but lacks liquidity risk assessment due to missing balance sheet data and no going-concern disclosures. The company's profitability metrics are not disclosed in the available data, preventing direct comparison to industry benchmarks for medical equipment firms. Advanced Medical Equipment & Technology companies typically emphasize R&D intensity and recurring revenue models, but Pro Medicus' specific financial performance against these metrics remains opaque. Geographic and segment revenue concentration data is not available in the current dataset, limiting analysis of exposure to specific markets or product lines. The company's business model likely centers on software licensing and service contracts, but detailed segment reporting is absent. Analyst price targets range from AUD 145.03 to AUD 247.00, with a mean of AUD 202.74 and median of AUD 202.75, suggesting a consensus for significant upside from current levels. The mean recommendation of 1.86 (on a 1-5 scale) indicates strong buy sentiment from 12 of 14 covering analysts. The risk assessment flags liquidity risk as unassessable due to missing balance sheet inputs, but dilution risk is rated low. No recent capital raises or share issuance programs are disclosed in the available documents, and the fully diluted share count equals the basic count. Recent events include the publication of analyst price targets and recommendations, but no material filings or earnings transcripts are available in the current dataset. The company's 2024 outlook remains unquantified in the provided data, though analyst expectations imply a potential 54% price appreciation from current levels.